Revolutionizing Breast Cancer Detection: From At-Home Screening to Breath Tests

For one in seven Irish women, a breast cancer diagnosis is a lifetime possibility. But a wave of new technologies is offering fresh hope, promising earlier detection, more personalized treatment, and a shift towards proactive breast health management. From at-home screening patches to breath tests capable of identifying cancer’s unique metabolic signature, the future of breast cancer detection is rapidly evolving.

The Challenges of Current Screening Methods

Currently, roughly half of eligible women participate in breast cancer screening programs. Access remains a significant barrier, particularly for women in their 40s and those with dense breasts. Approximately 50% of women have dense breast tissue, which can obscure tumors on mammograms, leading to missed diagnoses. Many women are unaware of their breast density, a critical factor in assessing risk and screening effectiveness. The Irish Cancer Society is advocating for lowering the screening age to 45, as 23% of Irish breast cancer diagnoses occur in women under 50, who currently have no access to routine screening.¹

At-Home Screening: A Wearable Patch for Early Detection

Feminai, co-founded by general surgeon Dr. Karny Ilan, is developing a disposable wearable patch designed for at-home breast cancer screening. The patch, used in conjunction with a smartphone app, stratifies women into risk groups and guides screening frequency. Users scan themselves with the patch, which connects via Bluetooth to the app, and results are sent to their physician. Early clinical trials at Sheba Medical Center have shown promising results, with 96% sensitivity and 98% negative predictive value.¹ This technology is particularly significant for women with dense breasts, where mammograms may be less accurate.

While not intended to replace mammography immediately, the goal is to complement existing examinations and empower women to capture control of their health. Feminai recently secured $6 million in seed funding and is initially focusing on the US and UK markets.¹

The Breath Test: Detecting Cancer Through Metabolic Signatures

Noze, a Canadian company led by CEO Karim Aly, is pioneering a breath test for breast cancer detection. This innovative approach leverages “digital odour perception” – teaching machines to identify the volatile organic compounds (VOCs) released in breath that change with the presence of cancer. The device doesn’t “smell cancer” directly, but rather reads biochemical signals from breath, offering a non-invasive alternative to traditional methods.¹

Noze’s “nose-on-a-chip” uses a miniaturized sensor and AI to analyze breath samples, identifying patterns indicative of cancer. Early clinical studies have demonstrated accuracy comparable to mammography, with a 97% negative predictive value, meaning it correctly identifies the absence of cancer in 97 out of 100 cases.¹ The initial focus is on reducing unnecessary biopsies, particularly for women with suspicious imaging, before expanding to broader screening applications.

Regulatory clearance for Noze’s first clinical breath test is anticipated in 2026, with plans to initially target markets where the necessitate is greatest.¹

Personalized Treatment Monitoring with Liquid Biopsies

Beyond detection, advancements are also being made in monitoring treatment effectiveness. Dr. Iseult Browne, a medical oncologist at The Royal Marsden Hospital and The Institute of Cancer Research, is researching the apply of liquid biopsies to track circulating tumor DNA (ctDNA). Measuring ctDNA levels in a blood sample can provide a real-time assessment of cancer activity.¹

Research indicates that a rapid decrease in ctDNA levels after treatment initiation correlates with a positive response, while stable or rising levels may signal treatment failure. Patients with undetectable ctDNA after four weeks of treatment had significantly longer progression-free survival. Ireland is actively participating in international ctDNA trials and building genomic infrastructure to facilitate the implementation of this technology in routine care within the next few years.¹

What You Can Do Now

• Realize Your Breasts: Regularly check your breasts and be familiar with how they normally perceive.
• Understand Your Risk: Discuss a comprehensive risk assessment with your doctor, including family history and breast density.
• If You’re in Your 20s-30s: Track your breasts throughout your cycle and establish a baseline with your GP.
• If You’re in Your 40s: Don’t delay discussing screening options with your doctor, especially if you have risk factors.
• If You’re 50+: Attend scheduled BreastCheck appointments and inquire about your breast density.
• Report Changes: Immediately report any lumps, swelling, skin changes, or nipple discharge to your doctor.

The Future of Breast Cancer Care

The convergence of at-home screening, breath tests, and personalized treatment monitoring represents a paradigm shift in breast cancer care. While widespread implementation in Ireland may take time, the potential to improve early detection rates, reduce unnecessary interventions, and enhance patient outcomes is immense. The future of breast cancer detection isn’t coming – it’s here, and it’s empowering women to prioritize their health and take control of their well-being.

This article is for information only and is not a substitute for medical advice. Always discuss screening and treatment decisions with your own doctor.